Syntheses of deuterium labeled prenyldiphosphate and prenylcysteine analogues for in vivo mass spectrometric quantification

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 56, Issue 8, 2013, Pages 370-375

  Subramanian, Thangaiah ^a   Subramanian, Karunai Leela ^b   Sunkara, Manjula ^b   Onono, Fredrick O ^a   Morris, Andrew J ^b   Spielmann, H Peter ^a,b,c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

AFPP; AGPP; FPP; FTase; GGPP; mass standards; protein prenylation; stable labeled synthesis

Indexed keywords

AMINATION; AMINO ACIDS; BIOSYNTHESIS; MASS SPECTROMETERS; MASS SPECTROMETRY;

AFPP; AGPP; FARNESOL; FPP; FTASE; GERANYLGERANIOL; GGPP; MASS STANDARD; PROTEIN PRENYLATION; STABLE LABELED SYNTHESIS;

DEUTERIUM;

2 AMINO 3 [[ 3,7,11 TRIMETHYL 12 (2,3,4,5,6 D5 PHENYLAMINO)DODECA 2,6,10 TRIEN 1 YL]THIO]PROPANOIC ACID; 2 AMINO 3 [[3,7 DIMETHYL 8 (2,3,4,5,6 D5 PHENYLAMINO)OCTA 2,6 DIEN 1 YL]THIO]PROPANOIC ACID; 3,7 DIMETHYL 8 (2,3,4,5,6 D5 PHENYLAMINO)OCTA 2,6 DIEN 1 YL DIPHOSPHATE; 3,7,11 TRIMETHYL 12 (D5 PHENYLAMINO)DODECA 2,6,10 TRIEN 1 YL DIPHOSPHATE; CYSTEINE DERIVATIVE; D6 FARNESOL; D6 FARNESYLCSYTEINE; D6 GERANYLGERANIOL; DEUTERIUM; FARNESOL; FARNESYL DIPHOSPHATE; GERANYLGERANIOL; ISOPRENOID; PYROPHOSPHATE; UNCLASSIFIED DRUG;

AMINATION; ARTICLE; CRYSTALLIZATION; IN VIVO STUDY; ISOTOPE LABELING; MASS SPECTROMETRY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTEIN PRENYLATION; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; WITTIG REACTION;

AFPP; AGPP; FPP; FTASE; GGPP; MASS STANDARDS; PROTEIN PRENYLATION; STABLE LABELED SYNTHESIS;

CYSTEINE; DEUTERIUM; ISOTOPE LABELING; MASS SPECTROMETRY; POLYISOPRENYL PHOSPHATES;

EID: 84880776374     PISSN: 03624803     EISSN: 10991344     Source Type: Journal    
DOI: 10.1002/jlcr.3049     Document Type: Article

References (44)

1. J. L. Goldstein, M. S. Brown, Regulation of the mevalonate pathway, Nature 1990, 343 (6257), 425-30.
2. J. Lombard, D. Moreira, Origins and early evolution of the mevalonate pathway of isoprenoid biosynthesis in the three domains of life, Mol. Biol. Evol. 2011, 28 (1), 87-99.
3. C. Garcia-Ruiz, A. Morales, J. C. Fernandez-Checa, Statins and protein prenylation in cancer cell biology and therapy, Anti-Cancer Agents Med Chem 2012, 12 (4), 303-315.
4. A. Rubinstein, National Cholesterol Education-Program, 2nd Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Circulation 1995, 91 (3), 908-909.
5. S. M. Grundy, National Cholesterol Education-Program, 2nd Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults-Reply, Circulation 1995, 91 (3), 909-909.
6. Detection, evaluation, and treatment of high blood cholesterol in adults-(Adult Treatment Panel-II), Circulation 1994, 89 (3), 1329-1445.
7. A. Corsini, F. M. Maggi, A. L. Catapano, Pharmacology of competitive inhibitors of Hmg-Coa reductase, Pharmacol. Res. 1995, 31 (1), 9-27.
8. F. M. Sacks, Hot papers- Coronary disease-The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels by F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, T.G. Cole, L. Brown, J.W. Warnica, J.M.O. Arnold, C.C. Wun, B.R. Davis, E. Braunwald-Comments, Sci. 1998, 12 (12), 11-11.
9. F. M. Sacks, et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N. Eng. J. Med. 1996, 335 (14), 1001-1009.
10. Tonkin, A., et al., Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N. Eng. J. Med. 1998, 339 (19), 1349-1357.
11. T. R. Pedersen, et al., Randomized trial of cholesterol-lowering in 4444 patients with coronary-heart-disease-the Scandinavian Simvastatin Survival Study (4s), Lancet 1994, 344 (8934), 1383-1389.
12. J. Shepherd, et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (Reprinted from N Engl J Med, vol 333, pg 1307-7, 1995), Atheroscler. Suppl. 2004, 5 (3), 91-97.
13. J. Shepherd, et al., Prevention of coronary heart-disease with pravastatin in men with hypercholesterolemia, N. Eng. J. Med. 1995, 333 (20), 1301-1307.
14. P. H. Jones, et al., Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial), Am. J. Cardiol. 2003, 92 (2), 152-160.
15. W. Hague, et al., Prevention and rehabilitation-effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study, Am. Heart J. 2003, 145 (4), 643-651.
16. A. Corsini, The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk, Cardiovasc. Drugs Ther. 2003, 17 (3), 265-285.
17. A. Blum, C. Simsolo, Y. Hasin, 3-Hydroxy-3-methylglutaryl coenzyme a (HMG-CoA) reductase inhibitors (statins), atherosclerosis and coronary syndromes, Atherosclerosis 2004, 175 (1), 1-5.
18. R. G. G. Russell, et al., Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy, Osteoporos. Int. 2008, 19 (6), 733-759.
19. P. Mansueto, et al., Mevalonate pathway: role of bisphosphonates and statins, Acta Med. Mediterr 2011, 27 (2), 85-95.
20. J. A. Tobert, Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors, Nat. Rev. Drug Discov. 2003, 2 (7), 517-526.
21. E. Oldfield, Targeting isoprenoid biosynthesis for drug discovery: bench to bedside, Acc Chem. Res 2010, 43 (9), 1216-1226.
22. G. Nurenberg, D. A. Volmer, The analytical determination of isoprenoid intermediates from the mevalonate pathway, Anal. Bioanal. Chem. 2012, 402 (2), 671-685.
23. D. C. Crick, D. A. Andres, C. J. Waechter, Farnesol is utilized for protein isoprenylation and the biosynthesis of cholesterol in mammalian-cells, Biochem. Biophys. Res. Commun. 1995, 211 (2), 590-599.
24. J. M. Troutman, et al., Tools to analyze protein farnesylation in cells, Bioconjug. Chem. 2005, 16 (5), 1209-1217.
25. L. G. Fong, et al., Activating the synthesis of progerin, the mutant prelamin A in Hutchinson-Gilford progeria syndrome, with antisense oligonucleotides, Hum. Mol. Genet. 2009, 18 (13), 2462-2471.
26. A. J. DeGraw, et al., Evaluation of alkyne-modified isoprenoids as chemical reporters of protein prenylation, Chem. Biol. Drug Des. 2010, 76 (6), 460-471.
27. Y. Kho, et al., A tagging-via-substrate technology for detection and proteomics of farnesylated proteins, Proc. Natl. Acad. Sci. U. S. A. 2004, 101 (34), 12479-12484.
28. L. N. Chan, et al., A novel approach to tag and identify geranylgeranylated proteins, Electrophoresis 2009, 30 (20), 3598-3606.
29. U. T. T. Nguyen, et al., Analysis of the eukaryotic prenylome by isoprenoid affinity tagging, Nat. Chem. Biol. 2009, 5 (4), 227-235.
30. F. O. Onono, et al., A tagging-via-substrate approach to detect the farnesylated proteome using two-dimensional electrophoresis coupled with Western blotting, Mol. Cell. Proteomics 2010, 9 (4), 742-751.
31. S. Miriyala, et al., Functional characterization of the atypical integral membrane lipid phosphatase PDP1/PPAPDC2 identifies a pathway for interconversion of isoprenols and isoprenoid phosphates in mammalian cells, J. Biol. Chem. 2010, 285 (18), 13918-13929.
32. K. A. H. Chehade, et al., Design and synthesis of a transferable farnesyl pyrophosphate analogue to Ras by protein farnesyltransferase, J. Org. Chem. 2000, 65 (10), 3027-3033.
33. J. M. Troutman, D. A. Andres, H. P. Spielmann, Protein farnesyl transferase target selectivity is dependent upon peptide stimulated product release, Biochemistry 2007, 46 (40), 11299-11309.
34. J. M. Troutman, et al., Selective modification of CaaX peptides with ortho-substituted anilinogeranyl lipids by protein farnesyl transferase: competitive substrates and potent inhibitors from a library of farnesyl diphosphate analogues, Biochemistry 2007, 46 (40), 11310-11321.
35. V. R. Adams, et al., Anticancer activity of novel unnatural synthetic isoprenoids, Anticancer Res. 2010, 30 (7), 2505-2512.
36. R. Nagel, J. Gershenzon, A. Schmidt, Nonradioactive assay for detecting isoprenyl diphosphate synthase activity in crude plant extracts using liquid chromatography coupled with tandem mass spectrometry, Anal. Biochem. 2012, 422 (1), 33-38.
37. E. Stokvis, H. Rosing, J. H. Beijnen, Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?, Rapid Commun. Mass Spectrom. 2005, 19 (3), 401-407.
38. D. J. Miller, et al., Stereochemistry of eudesmane cation formation during catalysis by aristolochene synthase from Penicillium roqueforti, Org. Biomol. Chem. 2008, 6 (13), 2346-2354.
39. D. J. Schenk, et al., Stereochemistry and deuterium isotope effects associated with the cyclization-rearrangements catalyzed by tobacco epiaristolochene and hyoscyamus premnaspirodiene synthases, and the chimeric CH4 hybrid cyclase, Arch. Biochem. Biophys. 2006, 448 (1-2), 31-44.
40. D. J. Comeskey, D. D. Rowan, A. J. Matich, Synthesis of d(8)-geranyl diphosphate, J. Label. Compd. Radiopharm. 2006, 49 (1), 47-54.
41. J. A. Marshall, A. M. Mikowski, Synthesis of a bistetrahydrofuran C17-C32 fragment of the polyether antibiotic ionomycin, Org. Lett. 2006, 8 (19), 4375-4378.
42. J. A. Marshall, R. K. Hann, A cascade cyclization route to adjacent bistetrahydrofurans from chiral triepoxyfarnesyl bromides, J. Org. Chem. 2008, 73 (17), 6753-6757.
43. G. R. Labadie, R. Viswanathan, C. D. Poulter, Farnesyl diphosphate analogues with omega-bioorthogonal azide and alkyne functional groups for protein farnesyl transferase-catalyzed ligation reactions, J. Org. Chem. 2007, 72 (24), 9291-9297.
44. S. A. Snyder, E. J. Corey, Concise total syntheses of palominol, dolabellatrienone, beta-araneosene, and isoedunol via an enantioselective Diels-Alder macrobicyclization, J. Am. Chem. Soc. 2006, 128 (3), 740-742.